Business Wire

TX-ROKA

26.4.2018 20:17:07 CEST | Business Wire | Press release

Share
Javier Gómez Noya Chooses ROKA Eyewear

ROKA , the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya , expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/

“I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of view.”

Gómez Noya began his partnership with ROKA four years ago, when he chose to compete in ROKA’s innovative line of wetsuits, swimskins, goggles, and triathlon race apparel. Over the past four years, Gómez Noya has worn ROKA to victory in three ITU World Triathlon Series titles, two IRONMAN 70.3 World Championships, and an Xterra Off-Road World Championship. Now he’ll be wearing ROKA optics as well as ROKA’s technical race and swim apparel as he attempts to win his first Ironman World Championship in Hawaii this year and cement his legacy as one of the greatest triathletes of all time.

"Javier has been with us every step of the way over the last four years, so we're thrilled to continue that partnership as we take on the challenge of creating the most advanced optics the world has ever seen," says ROKA CEO and Co-Founder, Rob Canales. "Having the input of an athlete of Javier's caliber is critical to the innovation and development of our products. That now includes our latest Maverick X wetsuit , our technical race apparel, and our advanced optics. We look forward to expanding our work with him to redefine standards in the performance eyewear market. It's about pushing limits, and nobody does that better than Javier.”

Gómez Noya will train and race in ROKA’s recently released Advanced Performance sunglasses, designed from scratch to be the lightest, highest performing, and most comfortable eyewear in the world, with unmatched field of vision and fit. “ROKA’s technical apparel and goggles have been a secret weapon for most of my world championships, and now I’m thrilled to have that same world-beating standard for my eyewear as I take on this new challenge of becoming Ironman World Champion,” Gómez Noya says. “My relationship with ROKA is about working together to make something better, and I’m confident that I now have the best eyewear team in the world in my corner for this next phase of my career.”

ROKA’s Advanced Performance eyewear is available in five styles and up to ten different lens tint options, giving athletes the ability to completely customize their eyewear to fit their specific needs. The unique design is the culmination of years of R&D by ROKA’s world-class team of designers and engineers. Weighing between 21 – 25 grams, the collection has set a new standard in the performance optics market that has to be felt to be believed.

Visit www.roka.com or email sales@roka.com to learn more about the company’s growing lines of premium performance eyewear, apparel, and equipment. Follow ROKA on social media at Facebook , Twitter , and Instagram .

About ROKA

ROKA started in a garage in Austin, Texas with humble beginnings and laser-beam focus. Our mission is to unlock human potential. To equip, empower, inspire, and ignite. We serve those who seek to redefine the standard, to push themselves to the limit – whatever and wherever that may be. When we see an opportunity to innovate, to challenge the status quo, to disrupt a complacent or monopolistic market, we go all in.

Since launching in 2016, ROKA eyewear has been worn to victory by multiple world champions across a variety of sports and challenges, from the Dakar Rally in South America to the Winter Olympics in PyeongChang, South Korea. Gómez Noya is one of 40 elite athletes from all walks of sport who will use Advanced Performance eyewear in 2018, helping them test their limits under the most extreme conditions. For more information, visit www.roka.com/contact

Contact:

Editorial contact
ROKA
Diane Thibert
VP Communications & Public Relations
(310) 804-2400 / diane@roka.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ROKASPORTS/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye